One-pot process for preparing intermediate of antibody-drug conjugate
The present invention relates to a “one-pot process” for preparing intermediate of antibody-drug conjugate. The preparation process provided by the present invention is simple in operation, and needs no such steps like concentration, washing and filtration of the intermediate reaction liquid, disposal of the organic waste liquid, and packaging and storage of the intermediate. The entire reaction system comprises only one separation and purification treatment, saving costs for labor, equipment, venues, raw materials, etc., and greatly reducing the pollution to the environment. In addition, the “one-pot process” for preparing intermediate of antibody-drug conjugate of the present invention produces the intermediate of antibody-drug conjugate with higher yield. The “one-pot process” for preparing intermediate of antibody-drug conjugate provided by the present invention is more suitable for scale-up production.
1. A process for preparing an intermediate of antibody-drug conjugate comprising a linker portion and a drug portion, wherein the intermediate of antibody-drug conjugate is Py-MAA-Val-Cit-PAB-D or MC-Val-Cit-PAB-D, wherein Py-MAA-Val-Cit-PAB or MC-Val-Cit-PAB in the intermediate is the linker portion, and D in the intermediate represents linked drug portion comprising free amino groups, wherein the process comprises the following reaction route:
wherein the preparation process is a one-pot process in which two steps are carried out in one system, wherein, the organic base 1 and the organic base 2 are each independently one or two of N,N-diisopropylethylamine and pyridine, and wherein the triazole catalyst is one or more of 1-hydroxybenzotriazole, 1-hydroxy-7-azobenzotriazole, 1-hydroxy-1H-1,2,3-triazole-4-carboxylic acid ethyl ester.
2. The process according to claim 1 , comprising reacting Py-MAA-Val-Cit-PAB-OH or MC-Val-Cit-PAB-OH with bis(4-nitrophenyl)carbonate (NPC) in the presence of an organic base, and after the completion of the above reaction, further adding organic base, and then adding 1-hydroxybenzotriazole and the drug portion D into the reaction system for further reaction.
3. The process according to claim 1 , wherein the drug portion D is auristatin cytotoxic agent, anthramycin cytotoxic agent, anthracycline cytotoxic agents or puromycin cytotoxic agent, or camptothecin analogs.
4. The process according to claim 3 , wherein the auristatin cytotoxic agent is MMAE, MMAF, MMAD or derivatives thereof; the anthramycin cytotoxic agent is anthramycin or derivative thereof; the anthracycline cytotoxic agent is daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone or derivatives thereof; the puromycin cytotoxic agent is puromycin or derivative thereof; and the camptothecin analogue is DX8951 or derivative thereof.
5. The process according to claim 4 , wherein Py-MAA-Val-Cit-PAB-D or MC-Val-Cit-PAB-D has a structure as shown in the following formulas (1-22):